The Takeovers Panel has declined to investigate Skin Elements Limited's allegations of undisclosed investor associations following a $2.5 million placement, after 62 Capital agreed to waive transfer restrictions on placement securities.
- Takeovers Panel declines to conduct proceedings on Skin Elements application
- 62 Capital waives enforcement of transfer restrictions in placement agreements
- Panel finds insufficient evidence of acting in concert among investors
- Placement involved 1.25 billion shares and 625 million options
- Undertaking removes potential regulatory concerns over voting control
Panel Rejects Skin Elements’ Application Over Alleged Investor Association
The Australian Takeovers Panel has opted not to proceed with an investigation into Skin Elements Limited’s (ASX:SKN) claims that certain placement investors and 62 Capital Pty Ltd were acting in concert ahead of critical board spill meetings. The application, lodged on 25 May 2026, alleged undisclosed associations that could affect voting control following SKN’s $2.5 million capital raise announced in October 2025.
Central to the Panel’s concerns was a clause in the subscription agreements between 62 Capital, as lead manager of the placement, and the placement investors. Clause 7 restricted the transfer or disposal of placement securities without 62 Capital’s consent, raising questions about whether this restriction effectively granted 62 Capital a relevant interest in the securities, potentially impacting voting rights under Chapters 6 and 6C of the Corporations Act.
62 Capital’s Undertaking Quells Regulatory Concerns
After the Panel requested further information, 62 Capital provided copies of the subscription agreements and clarified that it had not entered into any arrangements to exercise voting or disposal rights beyond the contractual clause. Importantly, 62 Capital has now undertaken not to enforce Clause 7 and committed to notifying all placement investors that they are released from this restriction.
This undertaking effectively removes the potential for 62 Capital to control or influence the transfer of placement shares and options, thereby addressing the Panel’s concerns about undisclosed relevant interests and possible shareholder associations.
Insufficient Evidence of Concerted Action Among Investors
Despite Skin Elements’ submission that 62 Capital and the placement investors were acting in concert, the Panel found the evidence insufficient to justify further inquiry. Without clear proof of coordinated action or association, the Panel concluded there was no reasonable prospect of declaring unacceptable circumstances.
The placement itself comprised 1.25 billion shares priced at $0.002 each, alongside 625 million unlisted options exercisable at $0.006. This capital raise has been a significant event for Skin Elements, underpinning its commercial activities in biotechnology and personal care products.
Implications for Skin Elements’ Governance and Market Perception
The Panel’s decision removes a layer of regulatory uncertainty that had shadowed Skin Elements’ upcoming board spill meetings, which hinge on shareholder voting power. By securing 62 Capital’s waiver of transfer restrictions, Skin Elements avoids potential complications around voting rights and investor disclosures that could have delayed or disrupted governance processes.
However, the Panel’s full reasons for the decision remain pending publication, leaving some ambiguity about the detailed legal interpretations. Market participants will be watching how Skin Elements manages investor relations and disclosure practices in the lead-up to its June 2026 meetings, especially given the prior concerns about undisclosed voting power raised by the company.
Bottom Line?
The Panel’s acceptance of 62 Capital’s undertaking defuses immediate regulatory risks for Skin Elements but leaves open questions about future investor coordination ahead of key governance votes.
Questions in the middle?
- Will Skin Elements face renewed scrutiny if investor coordination emerges ahead of board meetings?
- How will the release from transfer restrictions affect trading and voting behaviour of placement investors?
- What details will the Panel reveal in its forthcoming reasons that might clarify legal boundaries for similar placements?